- Home
- UTMD vs CUE Comparison
UTMD vs CUE Comparison
Compare UTMD & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UTMD | CUE |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.7M | 233.5M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | UTMD | CUE |
|---|---|---|
| Price | $74.20 | $38.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 22.0K | ★ 144.0K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $38,520,000.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $44.65 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $53.66 | $0.17 |
| 52 Week High | $75.75 | $45.50 |
Technical Indicators
Market Signals| Indicator | UTMD | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 69.70 |
| Support Level | $68.77 | $24.35 |
| Resistance Level | $75.38 | $41.42 |
| Average True Range (ATR) | 1.47 | 3.24 |
| MACD | 0.38 | 1.23 |
| Stochastic Oscillator | 86.09 | 86.62 |
Price Performance
Historical ComparisonAbout UTMD Utah Medical Products Inc.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.